Suspected adverse events following immunization associated with seperate/combined administration of 13-valent pneumococcal polysaccharide conjugate vaccine and oral pentavalent human rotavirus live attenuated vaccine in age-eligible children in a district of Shanghai
10.19428/j.cnki.sjpm.2025.24256
- VernacularTitle:上海市某区适龄儿童13价肺炎球菌多糖结合疫苗和口服五价轮状病毒减活疫苗单独/联合接种的疑似预防接种异常反应
- Author:
Jinyan CHEN
1
;
Hong PANG
1
Author Information
1. Changning District Center for Disease Control and Prevention (Changning District Health Supervision Institute), Shanghai 200335, China
- Publication Type:Journal Article
- Keywords:
13-valent pneumococcal conjugate vaccine;
oral pentavalent human rotavirus live attenuated vaccine;
standalone vaccination;
simultaneous vaccination;
adverse events following immunization;
safety
- From:
Shanghai Journal of Preventive Medicine
2025;37(3):234-238
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo analyze the safety of simultaneous vaccination of 13-valent pneumococcal conjugate vaccine (PCV13) and oral pentavalent human rotavirus live attenuated vaccine (RV5) in age-eligible children in Changning District, Shanghai. MethodsAdverse events following immunization (AEFI) and vaccination information after PCV13 and RV5 vaccination from Jan.1, 2022 to Dec.31, 2023 were collected through the National Immunization Program Information Management System and the Shanghai Immunization Information System in Changning District. We compared the incidence rates of AEFI reports after PCV13 and RV5 standalone and simultaneous vaccination. ResultsPCV13 was administered standalone in 7 654 doses, with 107 AEFI reports and an AEFI reporting rate of 1 397.96/100 000, including 1 371.83/100 000 for general reactions (105 cases) and 26.13/100 000 for abnormal reactions (2 cases). RV5 was administered standalone in 8 114 doses, with 30 AEFI reports and an AEFI reporting rate of 369.73/100 000, all of which were general reactions. PCV13 and RV5 were administered simultaneously in 6 731 doses, with 56 AEFI reports and an AEFI reporting rate of 831.97/100 000, including 802.26/100 000 for general reactions (54 cases), 14.86/100 000 for abnormal reactions (1 case), and 14.86/100 000 for coupling symptoms (1 case). ConclusionThe incidence rates of AEFI reports after PCV13 and RV5 vaccination standalone or simultaneous among age-eligible children in Changning District are within an acceptable range, primarily consisting of general reactions. PCV13 and RV5 simultaneous vaccination did not increase the risk of AEFI incidence.
